title: PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
abstract: Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Shi
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Shafei
authors.initials: S
authors.lastname: Wu
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Zeng
authors.affiliation: Peking Union Medical College Hospital, Department of Pathology, Beijing, 100730, China.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Liang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D060890:B7-H1 Antigen / Q000235:genetics* / Q000378:metabolism; D014408:Biomarkers, Tumor; D018196:Carcinoma, Adenosquamous / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009857:Oncogenes; D047368:Tumor Burden
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human